Silence Therapeutics (NASDAQ:SLN) Stock Price Down 3.5%

Silence Therapeutics plc (NASDAQ:SLN)’s stock price was down 3.5% during trading on Tuesday . The stock traded as low as $18.09 and last traded at $18.09. Approximately 25,249 shares changed hands during trading, a decline of 87% from the average daily volume of 197,378 shares. The stock had previously closed at $18.74.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Chardan Capital upped their price target on shares of Silence Therapeutics from $42.00 to $55.00 and gave the company a “buy” rating in a research report on Friday. Morgan Stanley boosted their price objective on shares of Silence Therapeutics from $45.00 to $49.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Thursday, June 27th.

Silence Therapeutics Stock Down 3.9 %

The company has a market cap of $539.04 million, a P/E ratio of -15.41 and a beta of 1.31. The firm’s 50 day moving average is $21.07 and its two-hundred day moving average is $21.05.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Thursday, May 16th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.18. The business had revenue of $15.73 million for the quarter, compared to analysts’ expectations of $4.53 million. Silence Therapeutics had a negative net margin of 131.44% and a negative return on equity of 79.90%. As a group, research analysts forecast that Silence Therapeutics plc will post -1.52 EPS for the current fiscal year.

Institutional Trading of Silence Therapeutics

A number of institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC boosted its position in Silence Therapeutics by 10.5% during the first quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock valued at $151,000 after acquiring an additional 667 shares during the last quarter. Parkman Healthcare Partners LLC raised its holdings in shares of Silence Therapeutics by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after purchasing an additional 40,063 shares during the period. Lynx1 Capital Management LP raised its holdings in shares of Silence Therapeutics by 123.4% during the first quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock valued at $11,375,000 after purchasing an additional 290,855 shares during the period. Vivo Capital LLC acquired a new position in shares of Silence Therapeutics during the fourth quarter valued at about $8,862,000. Finally, Janus Henderson Group PLC acquired a new position in shares of Silence Therapeutics during the first quarter valued at about $13,575,000. Institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.